IP Library › Granted Patent US 12,508,342
Granted Patent B2
US 12,508,342 · App. 17/206,822 · Granted Dec 30, 2025

Debridement composition

Inventors: David Parsons (Flintshire, GB); Genevieve E. Harris (Flintshire, GB); Hollie J. Hathaway (Flintshire, GB)
Assignee: CONVATEC LIMITED
A61L15/42A61L15/20A61L15/28A61L15/48A61L2300/208A61L2300/21A61L2300/216A61L2300/802A61L2420/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,508,342
App. No.
17/206,822
Granted
Dec 30, 2025
Kind
B2
Abstract

The disclosed technology relates to a wound dressing comprising an absorbent layer impregnated or coated with a composition comprising a chelating agent, an amphoteric surfactant, and an anionic surfactant. The invention further relates to methods and uses of the wound dressing.

Claims (42)

1 . A wound dressing or debridement tool comprising an absorbent layer impregnated or coated with a composition comprising

a chelating agent present at 0.01 to 1 wt. % and comprises a salt of ethylenediaminetetra-acetic acid (EDTA),

an amphoteric surfactant present at 0.01 to 1.5 wt. % and comprises sodium cocoamphoacetate, and

an anionic surfactant present at 0.05 to 1.5 wt. % and comprises sodium oleate.

2 . The wound dressing or debridement tool of claim 1 , wherein the anionic surfactant is present at 0.1 to 1 wt % or 0.1 to 0.5 wt %.

3 . The wound dressing or debridement tool of claim 1 , wherein the anionic surfactant further comprises an anionic surfactant chosen from a fatty acid or fatty acid salt, a sulphate, a sulphosuccinate, a sarcosine, a sarcosinate, an isethionate, a glutamate, or a taurate.

4 . The wound dressing or debridement tool of claim 1 , wherein the amphoteric surfactant is present at 0.02 to 0.8 wt % or 0.05 to 0.5 wt %.

5 . The wound dressing or debridement tool of claim 1 , wherein the amphoteric surfactant further comprises an amphoteric surfactant chosen from an hydrocarbyl-amphoacetate, alkenyl-amphoacetate, hydrocarbyl-amphodiacetate, alkenyl-amphodiacetate, hydrocarbylampho-propionate, hydrocarbylampho-dipropionate, or hydrocarbylamphohydroxypropyl sultaine, wherein the hydrocarbyl and alkenyl groups contain 6 to 24, or 8 to 24 carbon atoms.

6 . The wound dressing or debridement tool of claim 1 , wherein the chelating agent is present at 0.1 to 0.75 wt % or 0.1 to 0.5 wt %.

7 . The wound dressing or debridement tool of claim 1 , wherein the chelating agent further comprises a chelating agent chosen from a hydroxy-carboxylic acid ester or amide acid, or salts thereof, an oxalate, or a phosphate.

8 . The wound dressing or debridement tool of claim 1 , wherein the composition is impregnated or coated in the wound dressing and comprises:

the chelating agent is present at 0.1 to 0.75 wt %,

the anionic surfactant is present at or 0.1 to 1 wt %, or

the amphoteric surfactant is present at or 0.02 to 0.8 wt %.

9 . The wound dressing or debridement tool of claim 1 , wherein the composition is impregnated or coated in the wound dressing and comprises:

the chelating agent is present at 0.1 to 0.5 wt %,

the anionic surfactant is present at 0.1 to 0.5 wt %

the amphoteric surfactant is present at or 0.05 to 0.5 wt %.

10 . The wound dressing or debridement tool of claim 1 , wherein the composition impregnated or coated in the wound dressing or debridement tool comprises:

the chelating agent is present at 0.1 to 0.5 wt % (or 0.15 to 1.5 gm −2 ),

the anionic surfactant is present at 0.1 to 0.5 wt % (or 0.15 to 1.5 gm −2 ), and

the amphoteric surfactant is present at or 0.05 to 0.4 wt % (or 0.075 to 0.6 gm −2 ).

11 . The wound dressing or debridement tool of claim 1 , wherein the composition impregnated or coated in the wound dressing or debridement tool further comprises:

an amphoteric surfactant chosen from an hydrocarbyl-amphoacetate, alkenyl-amphoacetate, hydrocarbyl-amphoacetate, alkenyl-amphoacetate, hydrocarbylampho-propionate, hydrocarbylampho-dipropionate, or hydrocarbylamphohydroxypropyl sultaine, wherein the hydrocarbyl groups contain 6 to 24, or 8 to 24 carbon atoms;

an anionic surfactant chosen from a fatty acid or fatty acid salt, sulphate, a sulphosuccinate, a sarcosine, a sarcosinate, an isethionate, taurate, and a glutamate; and

a chelating agent chosen from a hydroxy-carboxylic acid ester or amide acid, or salts thereof (for example a citrate, tartrate, tartramide, or tartrimide, gluconic acid, a gluconate, a lactate, lactic acid, glycolic acid, or glycolate), an oxalate, or a phosphate.

12 . The wound dressing or debridement tool of claim 1 , wherein the composition impregnated or coated in the wound dressing further comprises:

an amphoteric surfactant chosen from an hydrocarbyl-amphoacetate, alkenyl-amphoacetate, hydrocarbyl-amphoacetate, alkenyl-amphoacetate, hydrocarbylampho-propionate, hydrocarbylampho-dipropionate, or hydrocarbylamphohydroxypropyl sultaine, wherein the hydrocarbyl groups contain 6 to 24, or 8 to 24 carbon atoms;

an anionic surfactant chosen from a fatty acid or fatty acid salt, a glutamate, a sulphosuccinate, a sarcosine, or a sarcosinate; and

a chelating agent chosen from an oxalate, a citrate, or a phosphate.

13 . The wound dressing or debridement tool of claim 1 , wherein the composition impregnated or coated in the wound dressing further comprises: a nonionic surfactant.

14 . The wound dressing of claim 13 , wherein the nonionic surfactant is present at 0.01 to 0.7 wt % (or 0.015 to 1.05 gm −2 ), or 0.05 to 0.5 wt % (or 0.075 to 0.75 gm −2 ), or 0.1 to 0.3 wt % (or 0.15 to 0.45 gm −2 ).

15 . The wound dressing or debridement tool of claim 1 , wherein the composition impregnated or coated in the wound dressing or debridement tool comprises:

the chelating agent is present at 0.01 to 1 wt % (or 0.015 to 1.5 gm −2 ),

the anionic surfactant is present at 0.05 to 1.5 wt % (or 0.075 to 2.25 gm −2 ),

the amphoteric surfactant is present at 0.01 to 1.5 wt % (or 0.015 to 2.25 gm −2 ), and

the nonionic surfactant is present at 0.01 to 0.7 wt % (or 0.015 to 1.05 gm −2 ).

16 . The wound dressing or debridement tool of claim 13 , wherein the nonionic surfactant is chosen from polyoxyethylene fatty acid esters, polyoxyethylene glycol fatty acid esters, sucrose fatty acid esters, poly-oxyethylene hydrogen carbonate castor oils, and polyoxyethylene alkyl ethers.

17 . The wound dressing or debridement tool of claim 1 , wherein the absorbent layer impregnated or coated with the composition comprises at least one layer composed of a foam, absorbent, or a gel-forming fibre.

18 . The wound dressing or debridement tool of claim 1 , wherein the wound dressing absorbent layer is a gel-forming fibre.

19 . The wound dressing or debridement tool of claim 1 , wherein the wound dressing absorbent layer is a gel-forming fibre, and wherein the fibre is chemically modified carboxymethylcellulose fibres.

20 . A composition comprising a chelating agent present at 0.01 to 1 wt. % and comprises a salt of ethylenediaminetetra-acetic acid (EDTA), an amphoteric surfactant present at 0.01 to 1.5 wt. % and comprises sodium cocoamphoacetate, and an anionic surfactant present at 0.05 to 1.5 wt. % and comprises sodium oleate for use in the treatment of a wound selected from the group consisting of a chronic wound, acute wound, burn, a wound comprising a bacterial biofilm, and a wound comprising slough.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2023
From: HARRIS, GENEVIEVE E; HATHAWAY, HOLLIE J
To: CONVATEC LIMITED
Reel/Frame 063906/0704 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2023
From: PARSONS, DAVID
To: CONVATEC LIMITED
Reel/Frame 063906/0751 →
Priority Claims (1)
GB 2004055 · Mar 20, 2020 · national
Continuity (2)
Continuation PCTGB2021050683 · Mar 19, 2021
Related Publication 20210290815A1 · Sep 23, 2021
References Cited (25)
US 6106854A · Belfer · 2000 [cited by examiner]
US 20020169405A1 · Roberts · 2002 [cited by applicant]
US 20110082105A1 · Fevola et al. · 2011 [cited by applicant]
US 20110118363A1 · Jensen · 2011 [cited by examiner]
US 20120039820A1 · Axe · 2012 [cited by examiner]
US 20120122755A1 · Sasa et al. · 2012 [cited by applicant]
US 20130150451A1 · Salamone · 2013 [cited by examiner]
US 20140227483A1 · Eaves, III · 2014 [cited by applicant]
US 20170151314A1 · Salamone et al. · 2017 [cited by applicant]
US 20170347661A1 · Parsons · 2017 [cited by applicant]
US 20190099300A1 · Ogawa et al. · 2019 [cited by applicant]
CN 102525832A · 2012 [cited by applicant]
CN 110559312A · 2019 [cited by applicant]
EP 3250244B1 · 2021 [cited by applicant]
GB 2531344A · 2014 [cited by applicant]
GB 2527617A · 2015 [cited by applicant]
JP 2007505124A · 2007 [cited by applicant]
JP 2011515136A · 2011 [cited by applicant]
JP 2015500794A · 2015 [cited by applicant]
JP 2016160264A · 2016 [cited by applicant]
WO 2008133724A2 · 2008 [cited by applicant]
WO 2017170956A1 · 2019 [cited by applicant]
WO 2019227034A1 · 2019 [cited by applicant]
International Search Report; European Patent Office; International Application No. PCT/GB2021/050683; Jun. 17, 2021; 3 pages. [cited by applicant]
Written Opinion of the International Searching Authority; European Patent Office; International Application No. PCT/GB2021/050683; Jun. 17, 2021; 6 pages. [cited by applicant]